RAPA 113
Alternative Names: RAPA-113Latest Information Update: 28 Nov 2022
Price :
$50 *
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Unspecified(Combination therapy, In volunteers) in South Korea (PO, Tablet)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 27 Nov 2019 Phase-I clinical trials in Unspecified (In volunteers) in South Korea (PO, Tablet) (NCT04171687)